NGM Bio is a clinical stage biopharmaceutical company that develops biologic drugs for the treatment of cardio-metabolic and liver disease.Read more
NGM Bio's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 4.5B. Over the last four quarters, NGM Bio's revenue has decreased by 2.9%. Specifically, in Q4 2021's revenue was $21M; in Q3 2021, it was $18.6M; in Q2 2021, it was $16.8M; in Q1 2021, NGM Bio's revenue was $21.6M.